jRCT2080224826已完成3 期
A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) with or without Pembrolizumab (MK-3475) in Participants with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- MSD K.K.
- 入组人数
- 530
- 试验地点
- 1
- 主要终点
- Event-free Survival (EFS)
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Randomized Controlled Trial,double Blind,placebo Control,parallel Assignment
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Has previously untreated NSCLC diagnosed by histology or cytology and confirmed as Stage I or II (T1 to limited T3, N0, M0) NSCLC (AJCC 8th edition) by chest CT and PET scan
- •Cannot undergo thoracic surgery due to existing medical illness(es) or anatomically unresectable tumor as determined by the
- •site's multidisciplinary tumor board. Medically operable participants who decide to treat with SBRT as definitive therapy rather than surgery are also eligible, if patient's unwillingness to undergo surgical resection is clearly documented
- •Has a ECOG Performance Status of 0, 1, or 2
- •Is able to receive SBRT and does not have an ultra-centrally located tumor
- •Has adequate organ function
- •A female is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: a) not a women of childbearing potential (WOCBP) OR b) A WOCBP and uses contraceptive method that is highly effective (with a failure rate of <1% per year), or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis), during the intervention period and for at least 120 days after the last dose of pembrolizumab/ placebo and 180 days after the last radiotherapy dose
- •Has a radiation therapy plan approved by the central radiation therapy quality assurance vendor
排除标准
- •Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4, OX-40, CD137)
- •Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or breast.Participants receiving radiotherapy to the contralateral breast at least 5 years prior to randomization may still be eligible
- •Has received a live vaccine within 30 days prior to the first dose of study intervention
- •Has received an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study intervention administration
- •Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment
- •Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded
- •Has a known hypersensitivity (>=Grade 3) to pembrolizumab and/or any of its excipients
- •Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
- •Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.No testing for hepatitis B and hepatitis C is required unless mandated by local health authority
- •Note: No testing for hepatitis B and hepatitis C is required unless mandated by local
- •health authority
- •Has an active autoimmune disease that has required systemic treatment in past 2 years, except replacement therapy
- •Has an active infection requiring systemic therapy
- •Has a known history of human immunodeficiency virus (HIV) infection
- •Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
- •Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of pembrolizumab/placebo and 180 days after the last radiotherapy dose
- •Has had an allogeneic tissue/solid organ transplant
结局指标
主要结局
Event-free Survival (EFS)
The time from randomization to an event defined as local, regional, or distant recurrence of the treated NSCLC or death from any cause.
次要结局
- Overall Survival(OS)
- Time to death or distant metastases(TDDM)
- safety and efficacy
- global health status/quality of life(QoL)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLCStage IV lung cancer conditionMedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004720-11-ROMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,792
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in 1L ES SCLCExtensive Stage Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004843-22-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co.,Inc699
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLCCTIS2023-509774-40-00Merck Sharp & Dohme LLC672
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in 1L ES SCLCExtensive Stage Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004843-22-CZMerck Sharp & Dohme Corp.699
进行中（未招募）
1 期
Phase 3 Study of Pembrolizumab with or without Maintenance Olaparib in First-Line Metastatic Squamous NSCLCMetastatic Squamous Non-small Cell Lung Cancer (NSCLC)MedDRA version: 20.0Level: LLTClassification code 10029514Term: Non-small cell lung cancer NOSSystem Organ Class: 100000004864EUCTR2018-004721-88-FRMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.735